Bitcoin price today: slips below $113k, near 6-wk low despite Fed cut bets
LONDON - Polar Capital Global Healthcare Trust plc has disclosed its top ten equity holdings as well as its sector and geographic exposure as of May 30, 2025. The announcement revealed a diverse portfolio with significant investments in pharmaceuticals and healthcare equipment companies.
The top ten equity positions include notable names such as Eli Lilly & Co (NYSE:LLY), AstraZeneca (NASDAQ:AZN), and Abbott Laboratories (NYSE:ABT), with each holding representing between 3.0% and 6.0% of the portfolio. Collectively, these top ten holdings constitute 42.8% of the Trust’s investments.
In terms of sector exposure, pharmaceuticals lead with 28.8%, followed by healthcare equipment at 23.7%, and biotechnology at 18.9%. The remaining sectors, including life sciences tools & services, healthcare supplies, and managed healthcare, among others, fill out the rest of the portfolio.
Geographically, the United States holds the largest share with 43.5% of the Trust’s investments. Other significant exposures include Denmark at 12.6%, Switzerland at 11.8%, and the United Kingdom (TADAWUL:4280) at 7.3%. The geographic spread continues with investments in Japan, the Netherlands, Belgium, Italy, Germany, Sweden, France, and Ireland.
The Trust’s monthly factsheet, which is expected to be available on the company’s website by the 10th working day following the month’s end, will provide further details and commentary from the investment manager.
This update offers a snapshot of Polar Capital Global Healthcare Trust’s investment focus and market positioning as of the end of May 2025. The information is based on a press release statement and has been issued by RNS, a news service of the London Stock Exchange (LON:LSEG), authorized by the Financial Conduct Authority in the UK.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.